Spina bifida

Introduction

Spina bifida is a congenital defect of the spinal cord resulting from incomplete closure of the neural tube during early embryonic development. It is a common neural tube defect that can lead to varying degrees of neurological impairment and physical disability. Early diagnosis and management are crucial for improving outcomes and quality of life.

Definition and Classification

Definition of Spina Bifida

Spina bifida is defined as a congenital malformation in which one or more vertebral arches fail to close properly, potentially exposing the spinal cord or meninges. The severity and clinical manifestations depend on the type and location of the defect.

Types of Spina Bifida

• Spina Bifida Occulta: The mildest form, where the vertebral defect is present but the spinal cord and meninges remain intact. Often asymptomatic and discovered incidentally.
• Meningocele: Protrusion of the meninges through the vertebral defect, forming a cerebrospinal fluid-filled sac. The spinal cord is usually unaffected.
• Myelomeningocele: The most severe form, involving protrusion of both the meninges and spinal cord. Associated with neurological deficits below the lesion.
• Myeloschisis: A rare and severe form in which the neural tissue remains exposed without a covering membrane, often leading to profound neurological impairment.

Severity Grading and Clinical Implications

The severity of spina bifida is determined by the size and location of the vertebral defect and the extent of neural involvement. Higher lesions and open defects are associated with more significant neurological deficits, including motor, sensory, and autonomic dysfunction.

Etiology and Risk Factors

Genetic Factors and Family History

Genetic predisposition plays a significant role in the development of spina bifida. Mutations or polymorphisms in genes involved in folate metabolism and neural tube closure can increase the risk. A positive family history of neural tube defects is an important predictor.

Environmental Factors

Maternal environmental conditions can contribute to neural tube defects. Insufficient folic acid intake during early pregnancy is a major risk factor, as folate is critical for DNA synthesis and neural tube formation.

Teratogenic Exposures

Exposure to certain medications, chemicals, or toxins during the first trimester can interfere with neural tube closure. Examples include valproic acid, methotrexate, and hyperthermia during early gestation.

Maternal Medical Conditions

Maternal health can influence the risk of spina bifida. Conditions such as pregestational diabetes, obesity, and poorly controlled metabolic disorders have been associated with an increased incidence of neural tube defects.

Embryology and Pathophysiology

Neural Tube Formation and Closure

The neural tube forms between the third and fourth week of embryonic development. Proper closure along the cranial and caudal ends is essential for normal spinal cord and vertebral formation. Failure of closure leads to spina bifida.

Mechanism of Neural Tube Defects

Disruptions in cell proliferation, migration, or differentiation during neural tube development can result in vertebral and spinal cord malformations. Both genetic and environmental factors can interfere with these processes.

Pathophysiologic Consequences on Spinal Cord and Nervous System

Open or protruding spinal cord tissue is vulnerable to injury, leading to neurological deficits. These can include motor weakness, sensory loss, and autonomic dysfunction affecting bladder and bowel control. Secondary complications such as hydrocephalus and tethered cord may develop over time.

Clinical Presentation

Symptoms of Spina Bifida Occulta

Spina bifida occulta is often asymptomatic and may remain undetected throughout life. Occasionally, subtle signs such as a tuft of hair, dimple, or small pigmentation on the lower back may indicate the presence of the defect.

Symptoms of Meningocele and Myelomeningocele

Meningocele usually presents as a fluid-filled sac on the back with minimal neurological impairment. In contrast, myelomeningocele involves both the spinal cord and meninges, leading to more pronounced neurological deficits, including muscle weakness, sensory loss, and impaired bladder or bowel function.

Neurological Deficits

• Motor deficits: lower limb weakness or paralysis
• Sensory deficits: loss of sensation below the lesion
• Bladder and bowel dysfunction: neurogenic bladder, incontinence

Associated Musculoskeletal Abnormalities

• Scoliosis and kyphosis
• Hip dislocation and contractures
• Clubfoot and other limb deformities

Hydrocephalus and Arnold-Chiari Malformation

Many children with myelomeningocele develop hydrocephalus due to obstruction of cerebrospinal fluid flow. Arnold-Chiari II malformation, characterized by downward displacement of cerebellar structures, is frequently associated and can contribute to neurological symptoms.

Diagnosis

Prenatal Diagnosis

• Maternal Serum Alpha-Fetoprotein: Elevated levels in maternal blood can indicate open neural tube defects.
• Ultrasound Imaging: Fetal ultrasound can detect spinal defects, associated hydrocephalus, and limb abnormalities.
• Fetal MRI: Provides detailed evaluation of the spinal cord, vertebrae, and associated central nervous system anomalies.

Postnatal Diagnosis

• Physical Examination Findings: Visible spinal defects, sac-like protrusions, skin stigmata, and neurological deficits.
• Radiologic Evaluation: X-ray, MRI, or CT scans help assess vertebral defects, spinal cord involvement, and associated abnormalities.
• Neurological Assessment: Evaluates motor and sensory function, bladder and bowel control, and reflexes to determine the extent of impairment.

Complications

Neurological Complications

• Paralysis or weakness of the lower limbs
• Sensory deficits affecting touch, pain, or temperature perception
• Tethered cord syndrome leading to progressive neurological deterioration

Urologic Complications

• Neurogenic bladder causing incontinence or urinary retention
• Recurrent urinary tract infections due to incomplete bladder emptying
• Risk of renal damage if untreated

Orthopedic Complications

• Spinal deformities such as scoliosis and kyphosis
• Hip dislocation, contractures, and limb malformations
• Foot deformities including clubfoot and abnormal gait

Infections

Open neural tube defects or postoperative wounds increase the risk of meningitis and other infections, which can exacerbate neurological damage.

Psychosocial and Cognitive Challenges

Children with spina bifida may experience learning difficulties, reduced social participation, and emotional challenges due to physical limitations and chronic health issues.

Treatment and Management

Medical Management

• Antibiotics for urinary tract infections or wound infections
• Bladder and bowel management through catheterization, medications, and dietary modifications
• Monitoring and treatment of hydrocephalus

Surgical Management

• Fetal Surgery: Prenatal repair of myelomeningocele to prevent further neurological damage and reduce complications.
• Postnatal Closure of Defects: Early surgical closure of the spinal defect to protect exposed neural tissue and prevent infection.
• Shunt Placement for Hydrocephalus: Ventriculoperitoneal or ventriculoatrial shunts to manage cerebrospinal fluid accumulation and reduce intracranial pressure.

Rehabilitation and Physical Therapy

Multidisciplinary rehabilitation including physiotherapy, occupational therapy, and gait training helps maximize mobility, strength, and functional independence.

Assistive Devices and Adaptive Technologies

Use of braces, wheelchairs, walkers, and other adaptive equipment supports mobility and daily activities, enhancing quality of life for affected individuals.

Prevention

Folic Acid Supplementation

Periconceptional folic acid supplementation significantly reduces the risk of neural tube defects. Women planning pregnancy are advised to take 400–800 micrograms of folic acid daily before conception and during the first trimester.

Maternal Health Optimization

Maintaining good maternal health through proper nutrition, glycemic control in diabetic women, and weight management can decrease the likelihood of spina bifida.

Avoidance of Teratogenic Exposures

Pregnant women should avoid medications and environmental toxins known to interfere with neural tube development, such as anticonvulsants, certain chemotherapeutic agents, and high-temperature exposure.

Genetic Counseling and Screening

Families with a history of neural tube defects should receive genetic counseling to assess risk. Preconception and early pregnancy screening can help identify at-risk pregnancies and guide preventive measures.

Prognosis

Factors Affecting Long-Term Outcomes

The prognosis depends on the type, location, and severity of the defect, as well as the presence of associated complications such as hydrocephalus or Arnold-Chiari malformation. Early intervention improves functional outcomes.

Quality of Life Considerations

With appropriate medical care, rehabilitation, and adaptive support, many individuals with spina bifida can lead productive lives. Continuous follow-up is essential to manage complications and support physical and psychosocial development.

Life Expectancy and Functional Independence

Life expectancy has improved significantly due to advances in medical and surgical care. Functional independence is influenced by mobility, bladder and bowel management, and cognitive abilities, emphasizing the importance of comprehensive care.

References

1. Moore KL, Persaud TVN, Torchia MG. The Developing Human: Clinically Oriented Embryology. 11th ed. Philadelphia: Elsevier; 2020.
2. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final Data for 2020. Natl Vital Stat Rep. 2022;71(17):1-30.
3. Adzick NS. Fetal surgery for spina bifida: an update. Curr Opin Obstet Gynecol. 2013;25(2):132-7.
4. Heffez DS, Kanim LE, Tong K, et al. Spina bifida: classification, pathophysiology, and prognosis. Neurosurg Clin N Am. 1990;1(2):295-308.
5. Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 2013;12(8):799-810.
6. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34(3):114-20.
7. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet. 2004;364(9448):1885-95.
8. Shin M, Kucik JE, Siffel C, et al. Epidemiology of spina bifida in the United States: 1998–2003. Am J Med Genet A. 2009;149A(10):2157-64.
9. Carter T, Wynne-Davies R. Orthopaedic aspects of spina bifida. J Bone Joint Surg Br. 1986;68(3):376-9.